{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:17:38Z","timestamp":1781511458183,"version":"3.54.1"},"reference-count":79,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Muscle Study Group, the American Academy of Neurology, the American Brain Foundation, and NIH\/NINDS","award":["K23NS118048"],"award-info":[{"award-number":["K23NS118048"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Myotonic dystrophy (DM) is the most common muscular dystrophy in adults. Dominantly inherited CTG and CCTG repeat expansions in DMPK and CNBP genes cause DM type 1 (DM1) and 2 (DM2), respectively. These genetic defects lead to the abnormal splicing of different mRNA transcripts, which are thought to be responsible for the multiorgan involvement of these diseases. In ours and others\u2019 experience, cancer frequency in patients with DM appears to be higher than in the general population or non-DM muscular dystrophy cohorts. There are no specific guidelines regarding malignancy screening in these patients, and the general consensus is that they should undergo the same cancer screening as the general population. Here, we review the main studies that investigated cancer risk (and cancer type) in DM cohorts and those that researched potential molecular mechanisms accounting for DM carcinogenesis. We propose some evaluations to be considered as malignancy screening in patients with DM, and we discuss DM susceptibility to general anesthesia and sedatives, which are often needed for the management of cancer. This review underscores the importance of monitoring the adherence of patients with DM to malignancy screenings and the need to design studies that determine whether they would benefit from a more intensified cancer screening than the general population.<\/jats:p>","DOI":"10.3390\/jcm12051939","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T03:57:49Z","timestamp":1677643069000},"page":"1939","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cancer and Myotonic Dystrophy"],"prefix":"10.3390","volume":"12","author":[{"given":"Eleonora S.","family":"D\u2019Ambrosio","sequence":"first","affiliation":[{"name":"Department of Neurology, Nationwide Children\u2019s Hospital, Columbus, OH 43205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3980-8555","authenticated-orcid":false,"given":"Paloma","family":"Gonzalez-Perez","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"ref_1","unstructured":"Harper, P.S. (2001). Myotonic Dystrophy, W.B. Saunders. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of State-wide Blood Screening Program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.1546326","article-title":"An Unstable Triplet Repeat in a Gene Related to Myotonic Muscular Dystrophy","volume":"255","author":"Fu","year":"1992","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ejhg.2011.23","article-title":"Population frequency of myotonic dystrophy: Higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland","volume":"19","author":"Suominen","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.1062125","article-title":"Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9","volume":"293","author":"Liquori","year":"2001","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","article-title":"The myotonic dystrophies: Molecular, clinical, and therapeutic challenges","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng704","article-title":"Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy","volume":"29","author":"Savkur","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1038\/ncomms11067","article-title":"Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy","volume":"7","author":"Freyermuth","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/hmg\/ddr568","article-title":"Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel","volume":"21","author":"Tang","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Koehorst, E., Ballester-Lopez, A., Arechavala-Gomeza, V., Mart\u00ednez-Pi\u00f1eiro, A., and Nogales-Gadea, G. (2020). The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123939"},{"key":"ref_12","first-page":"344","article-title":"Myopathies and Cancer","volume":"Volume 2","author":"Grisold","year":"2021","journal-title":"Effects of Cancer Treatment on the Nervous System"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/WCO.0000000000001091","article-title":"Update on dermatomyositis","volume":"35","author":"Tanboon","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/brain\/121.8.1557","article-title":"Age and causes of death in adult-onset myotonic dystrophy","volume":"121","author":"Thijs","year":"1998","journal-title":"Brain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1212\/WNL.52.8.1658","article-title":"A 10-year study of mortality in a cohort of patients with myotonic dystrophy","volume":"52","author":"Mathieu","year":"1999","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1468-1331.2006.01261.x","article-title":"Survival and mortality of myotonic dystrophy type 1 (Steinert\u2019s disease) in the population of Belgrade","volume":"13","author":"Pekmezovic","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/mus.21934","article-title":"Survival and CTG repeat expansion in adults with myotonic dystrophy type 1","volume":"43","author":"Groh","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gadalla, S.M., Pfeiffer, R.M., Kristinsson, S.Y., Bj\u00f6rkholm, M., Hilbert, J.E., Moxley, R.T., Landgren, O., and Greene, M.H. (2013). Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079851"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1212\/WNL.0000000000003124","article-title":"Cancer risk in DM1 is sex-related and linked to miRNA-200\/141 downregulation","volume":"87","author":"Emparanza","year":"2016","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1001\/jama.2011.1796","article-title":"Cancer Risk Among Patients With Myotonic Muscular Dystrophy","volume":"306","author":"Gadalla","year":"2011","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00415-012-6476-8","article-title":"Correlates of tumor development in patients with myotonic dystrophy","volume":"259","author":"Das","year":"2012","journal-title":"J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.mayocp.2011.09.005","article-title":"Increased Cancer Risks in Myotonic Dystrophy","volume":"87","author":"Win","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mus.25145","article-title":"A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy","volume":"54","author":"Abbott","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/mus.25736","article-title":"Benign and malignant tumors in the UK myotonic dystrophy patient registry","volume":"57","author":"Alsaggaf","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/(SICI)1097-4598(200005)23:5<804::AID-MUS19>3.0.CO;2-E","article-title":"CTG triplet repeat expansion in a laryngeal carcinoma from a patient with myotonic dystrophy","volume":"23","author":"Osanai","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0190-9622(03)00125-7","article-title":"Tissue and tumor mosaicism of the myotonin protein kinase gene trinucleotide repeat in a patient with multiple basal cell carcinomas associated with myotonic dystrophy","volume":"50","author":"Botella","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/(SICI)1097-4598(199909)22:9<1271::AID-MUS16>3.0.CO;2-D","article-title":"Elongation of (CTG)n repeats in myotonic dystrophy protein kinase gene in tumors associated with myotonic dystrophy patients","volume":"22","author":"Jinnai","year":"1999","journal-title":"Muscle Nerve"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<622::AID-MUS16>3.0.CO;2-Y","article-title":"Differences in CTG triplet repeat expansions in an ovarian cancer and cyst from a patient with myotonic dystrophy","volume":"20","author":"Kinoshita","year":"1997","journal-title":"Muscle Nerve"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1016\/j.lpm.2013.01.052","article-title":"Increasing risk of tumors in myotonic dystrophy type 1","volume":"42","author":"Mohamed","year":"2013","journal-title":"Presse Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ijc.31143","article-title":"Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink","volume":"142","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"pky052","DOI":"10.1093\/jncics\/pky052","article-title":"Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity","volume":"2","author":"Alsaggaf","year":"2018","journal-title":"JNCI Cancer Spectr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/mus.26194","article-title":"Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis","volume":"58","author":"Emparanza","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio, E.S., Chuang, K., David, W.S., Amato, A.A., and Gonzalez-Perez, P. (Muscle Nerve, 2023). Frequency and Type of Cancers in Myotonic Dystrophy. A Retrospective Cross-Sectional Study, Muscle Nerve, in press.","DOI":"10.1002\/mus.27801"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00415-015-8006-y","article-title":"Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors","volume":"263","author":"Bianchi","year":"2016","journal-title":"J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10552-009-9395-y","article-title":"Hypothesis: Neoplasms in myotonic dystrophy","volume":"20","author":"Mueller","year":"2009","journal-title":"Cancer Causes Control."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00403-009-0997-8","article-title":"Association between basal, squamous cell carcinomas, dysplastic nevi and myotonic muscular dystrophy indicates an important role of RNA-binding proteins in development of human skin cancer","volume":"302","author":"Zemtsov","year":"2009","journal-title":"Arch. Dermatol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1440-1827.2001.01231.x","article-title":"beta-Catenin gene mutation in human hair follicle-related tumors","volume":"51","author":"Kajino","year":"2001","journal-title":"Pathol. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.0303-6987.2005.00267.x","article-title":"Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin","volume":"32","author":"Lazar","year":"2005","journal-title":"J. Cutan. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/7747","article-title":"A common human skin tumour is caused by activating mutations in beta-catenin","volume":"21","author":"Chan","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.21400","article-title":"Wnt pathway is involved in pleomorphic adenomas induced by overexpression of PLAG1 in transgenic mice","volume":"118","author":"Zhao","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/hmg\/5.Supplement_1.1417","article-title":"Myotonic dystrophy: Will the real gene please step forward!","volume":"5","author":"Harris","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ng0294-152","article-title":"Instability of short tandem repeats (microsatellites) in human cancers","volume":"6","author":"Wooster","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/mc.23030","article-title":"CNBP controls tumor cell biology by regulating tumor-promoting gene expression","volume":"58","author":"Lee","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaad.2014.09.038","article-title":"Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: A cross-sectional study","volume":"72","author":"Zampetti","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","first-page":"114","article-title":"Somatic heterogeneity of the CTG repeat in myotonic dystrophy is age and size dependent","volume":"56","author":"Wong","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-5876(00)00449-3","article-title":"Head and neck pilomatricoma in the pediatric age group: A retrospective study and literature review","volume":"57","author":"Yencha","year":"2001","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_47","first-page":"1","article-title":"Pilomatrixoma of the breast in a patient with type 1 myotonic dystrophy: Successful surgical approach","volume":"30","author":"Ieni","year":"2016","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/pde.13947","article-title":"Syndromes associated with multiple pilomatricomas: When should clinicians be concerned?","volume":"37","author":"Ciriacks","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_49","first-page":"124","article-title":"Multiple pilomatrixomas and myotonic dystrophy: A case report","volume":"58","author":"Salerni","year":"1988","journal-title":"Riv. di Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"117212","DOI":"10.1016\/j.jns.2020.117212","article-title":"Cancer frequency among the patients with myotonic dystrophy in the South Korean population using the national health insurance database","volume":"420","author":"Park","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/ced.15214","article-title":"A newly growing asymptomatic facial lesion","volume":"47","author":"Butt","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"R\u00fcbben, A., Wahl, R.U., Eggermann, T., Dahl, E., Ortiz-Br\u00fcchle, N., and Cacchi, C. (2020). Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype. PLoS ONE, 15.","DOI":"10.1101\/844647"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"ref_54","first-page":"387","article-title":"Myotonia atrophica and multiple calcifying epithelioma of Malherbe","volume":"45","author":"Cantwell","year":"1965","journal-title":"Acta Dermato-Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13023-019-1019-3","article-title":"Systematic thyroid screening in myotonic dystrophy: Link between thyroid volume and insulin resistance","volume":"14","author":"Espiard","year":"2019","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/acn3.50856","article-title":"Benign tumors in myotonic dystrophy type I target disease-related cancer sites","volume":"6","author":"Alsaggaf","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D31TD0145C","article-title":"Multiple pilomatricomas: Case presentation and review of the literature","volume":"16","author":"Chan","year":"2010","journal-title":"Dermatol. Online J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/DAD.0000000000001296","article-title":"Multiple Pilomatricomas: A Retrospective Study and Literature Review","volume":"41","author":"Batalla","year":"2019","journal-title":"Am. J. Dermatopathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1111\/ced.13946","article-title":"Multiple pilomatrixomas as a presentation of myotonic dystrophy","volume":"44","author":"Kentley","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e227233","DOI":"10.1136\/bcr-2018-227233","article-title":"Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1","volume":"12","author":"Feng","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF02913913","article-title":"Multiple thymoma with myotonic dystrophy","volume":"49","author":"Hirai","year":"2001","journal-title":"Jpn. J. Thorac. Cardiovasc. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1007\/BF01308090","article-title":"Intestinal carcinoid tumor and myotonic dystrophy","volume":"37","author":"Reimund","year":"1992","journal-title":"Dig. Dis. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/jnnp.51.12.1578","article-title":"Myotonic dystrophy and hyperparathyroidism: Association with neurofibromatosis and multiple endocrine adenomatosis type 2A","volume":"51","author":"Rosenberg","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/CPJ.0000000000000645","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 2","volume":"9","author":"Schoser","year":"2019","journal-title":"Neurol. Clin. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/qjmed\/os-8.30.114","article-title":"Observations on Thomsen\u2019s Disease","volume":"8","author":"Johnson","year":"1915","journal-title":"QJM Int. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1213\/00000539-195211000-00055","article-title":"Thiopentone in dystrophia myotonica","volume":"31","author":"Dundee","year":"1952","journal-title":"Anesth. Analg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/bja\/29.1.35","article-title":"Thipentone in dystrophia myotonica","volume":"29","author":"Bourke","year":"1957","journal-title":"Br. J. Anaesth."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1212\/WNL.49.6.1646","article-title":"Anesthetic and surgical complications in 219 cases of myotonic dystrophy","volume":"49","author":"Mathieu","year":"1997","journal-title":"Neurology"},{"key":"ref_69","first-page":"183","article-title":"Anaesthesia in dystrophia myotonica: A review of the hazards of anaesthesia","volume":"53","author":"Kaufman","year":"1960","journal-title":"Proc. R. Soc. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1460-9592.2009.03079.x","article-title":"Risk factors for perioperative adverse events in children with myotonic dystrophy","volume":"19","author":"Sinclair","year":"2009","journal-title":"Pediatr. Anesth."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41598-020-76217-9","article-title":"Opioid use may be associated with postoperative complications in myotonic dystrophy type 1 with high-grade muscular impairment","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00000542-198408000-00011","article-title":"The response of Patients with Neuromuscular Disorders to Muscle Relaxants: A Review","volume":"61","author":"Azar","year":"1984","journal-title":"Anesthesiology"},{"key":"ref_73","unstructured":"Ferschi, M., Moxley, R., Day, J.W., and Gropper, M. (2023, February 06). Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient. Myotonic Dystrophy Foundation. Care and a Cure. Available online: Myotonic.org\/sites\/default\/files\/MDF_LongForm_AnesGuidelines_01C.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/bja\/39.10.815","article-title":"The myotonic response to suxamethonium","volume":"39","author":"Thiel","year":"1967","journal-title":"Br. J. Anaesth."},{"key":"ref_75","first-page":"872","article-title":"Vecuronium for Muscle Relaxation in Patients with Dystrophia Myotonica","volume":"76","author":"Diefenbach","year":"1993","journal-title":"Obstet. Anesth. Dig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/pan.12120","article-title":"Myotonic Dystrophies type 1 and 2: Anesthetic care","volume":"23","author":"Veyckemans","year":"2013","journal-title":"Pediatr. Anesth."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1468-1331.2009.02942.x","article-title":"Side effects of anesthesia in DM2 as compared to DM1: A comparative retrospective study","volume":"17","author":"Kirzinger","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1111\/ene.15526","article-title":"European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders","volume":"29","author":"Heytens","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pediatrneurol.2020.08.001","article-title":"A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)","volume":"112","author":"Horrigan","year":"2020","journal-title":"Pediatr. Neurol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1939\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:45:01Z","timestamp":1760121901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":79,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12051939"],"URL":"https:\/\/doi.org\/10.3390\/jcm12051939","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}